Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Although no therapies are approved for light chain (AL) amyloidosis, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is considered standard of care. Based on outcomes of daratumumab in multiple myeloma (MM), the phase 3 ANDROMEDA study (NCT03201965) is evaluating daratumumab-CyBorD vs CyBor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Palladini, Giovanni, Kastritis, Efstathios, Maurer, Mathew S., Zonder, Jeffrey, Minnema, Monique C., Wechalekar, Ashutosh D., Jaccard, Arnaud, Lee, Hans C., Bumma, Naresh, Kaufman, Jonathan L., Medvedova, Eva, Kovacsovics, Tibor, Rosenzweig, Michael, Sanchorawala, Vaishali, Qin, Xiang, Vasey, Sandra Y., Weiss, Brendan M., Vermeulen, Jessica, Merlini, Giampaolo, Comenzo, Raymond L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7332897/
https://ncbi.nlm.nih.gov/pubmed/32244252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019004460
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados